ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
자반증 치료 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 향후 시장 확장은 생물학적 치료법의 개발, 유전자 검사에 대한 수요 증가, 조기 진단을 위한 원격 의료에 대한 의존도 증가, 희귀 질환 치료에 대한 규제 인센티브, 맞춤형 치료 접근 방식으로의 전환으로 인해 촉진될 것입니다. 예측 기간 동안 예상되는 주요 동향은 유전자 기반 치료법의 진보, 세포 치료 혁신, 고정밀 약물 전달 기술, 웨어러블 진단 도구의 채택, 나노 기술 기반 의료 진보 등입니다.
자가면역 질환의 유병률 증가는 자반증 치료 시장의 확대를 촉진할 것으로 예측됩니다. 자가면역 질환은 신체의 면역 체계가 박테리아나 바이러스와 같은 해로운 침입자라고 믿고 자신의 건강한 세포와 조직을 잘못 공격할 때 발생합니다. 종종 환경적 유인이 염증과 분자 모방을 촉진함으로써 이런 원인이 되어 면역계가 몸 자신의 조직을 공격하게 되어 자가면역 질환의 위험 자외선 질환의 치료는 과도한 면역 반응을 억제하고 혈소판 생산을 촉진하고 혈관의 염증을 억제함으로써자가 면역 질환의 관리에 중요한 역할을합니다. 이는 면역 혈소판 감소성 자반증(ITP)과 같은 자가면역 관련 자반증에서 흔히 볼 수 있는 멍, 출혈, 낮은 혈소판 수치와 같은 증상을 조절하는 데 도움이 됩니다. Office for Health Improvement &Disparities가 발표한 보고서에 따르면, 2022년에는 16세 이상의 17.6%가 장기 근골격계(MSK) 질환을 가지고 있다고 보고했으며, 2021년의 17.0%로부터 증가한 수치입니다. 따라서 자가면역 질환 유병률의 증가는 자반증 치료 시장의 성장을 촉진하고 있습니다.
맞춤형 의료에 대한 수요 증가도 자반증 치료 시장을 끌어 올릴 것으로 예측됩니다. 생명 공학의 진보는 개별 유전자 프로파일에 맞는 보다 정확하고 효과적인 치료를 가능하게하고, 궁극적으로 환자의 결과를 개선하고 부작용을 최소화 할 수있게되었습니다. 치료는 유전자와 면역계의 데이터를 이용하여 치료를 커스터마이징함으로써 환자 독자적인 생물학적 반응에 기초하여 치료 효과를 개선하고 부작용을 경감합니다. 2022년에는 새롭게 승인된 12개의 개별화 의약품이 그 해에 승인된 전신치료법의 약 34%를 차지하고 이전부터의 대폭적인 성장을 반영하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 자반증 치료:PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 자반증 치료 시장 : 성장률 분석
세계의 자반증 치료 시장 실적 : 규모와 성장, 2019-2024
세계의 자반증 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 자반증 치료 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 자반증 치료 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
비혈소판 감소성 자반병
혈소판 감소성 자반병
알레르기성 자반병
세계의 자반증 치료 시장 : 치료유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
국소 치료
경구약
유리체내 주사
레이저 요법
광선역학요법
세계의 자반증 치료 시장 : 케이스별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
급성
만성
세계의 자반증 치료 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
온라인 약국
소매 약국
세계의 자반증 치료 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
기타 최종 사용자
세계의 자반증 치료 시장 : 비혈소판 감소성 자반병 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
특발성 자반병
노인성 자반병
자반혈관 이상
세계의 자반증 치료 시장 : 혈소판 감소성 자반병 병형별 서브세그먼테이션, 분석과 예측, 2019-2024, 2024-2029F, 2034F
면역혈소판 감소성 자반병(ITP)
약제 유발성 혈소판 감소성 자반병
2차성 혈소판 감소성 자반병
세계의 자반증 치료 시장 : 알레르기성 자반병유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
약제 유발성 알레르기성 자반병
식품유발성 알레르기성 자반병
감염 관련 알레르기성 자반병
제7장 지역별/국가별 분석
세계의 자반증 치료 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 자반증 치료 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
자반증 치료 시장 : 경쟁 구도
자반증 치료 시장 : 기업 프로파일
Merck & Co Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Takeda Pharmaceutical Company Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Amgen Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
CSL Limited
Intas Pharmaceuticals Ltd.
Biogen Inc.
Chugai Pharmaceutical Co Ltd.
Sun Pharmaceutical Industries Limited
Octapharma AG
Grifols SA
GC Pharma
Emergent BioSolutions Inc.
Kissei Pharmaceutical Co Ltd.
Ablynx NV
Shire plc
Lee's Pharmaceutical Holdings Limited
Omeros Corporation
KM Biologics Co Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
자반증 치료 시장(2029년) : 새로운 기회를 제공하는 국가
자반증 치료 시장(2029년) : 새로운 기회를 제공하는 부문
자반증 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Purpura treatment refers to the medical care and management of purpura, which are purple-colored spots or patches on the skin caused by small blood vessels leaking under the skin. Purpura treatment is utilized by healthcare providers to manage symptoms and address underlying conditions such as platelet disorders, infections, or autoimmune diseases that cause bleeding under the skin.
The main types of purpura treatment include non-thrombocytopenic purpura, thrombocytopenic purpura, and allergic purpura. Non-thrombocytopenic purpura is characterized by bleeding under the skin, resulting in red or purple discoloration (purpura). These conditions are managed through different treatment approaches, such as topical therapies, oral medications, intravitreal injections, laser treatments, and photodynamic therapy. Purpura may present as either acute or chronic cases and is distributed through several channels, including hospital pharmacies, online pharmacies, and retail pharmacies. The treatments are utilized by various end users, such as hospitals, clinics, and other healthcare facilities.
The purpura treatment market research report is one of a series of new reports from The Business Research Company that provides purpura treatment market statistics, including purpura treatment industry global market size, regional shares, competitors with a purpura treatment market share, purpura treatment market segments, market trends and opportunities, and any further data you may need to thrive in the purpura treatment industry. This purpura treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The purpura treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The historical growth has been driven by the introduction of new therapeutic options, increased use of corticosteroids, growth in clinical research initiatives, rising healthcare expenditure, and improvements in hospital facilities.
The purpura treatment market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. Future market expansion will be fueled by the development of biologic therapies, rising demand for genetic screening, increased reliance on telehealth for early diagnosis, regulatory incentives for rare disease treatments, and a shift toward customized treatment approaches. Key trends anticipated during the forecast period include progress in gene-based therapies, innovations in cell therapy, precision drug delivery technologies, adoption of wearable diagnostic tools, and advancements in nanotechnology-based medicine.
The growing prevalence of autoimmune diseases is expected to drive the expansion of the purpura treatment market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues, believing they are harmful invaders such as bacteria or viruses. Environmental triggers often contribute to this by promoting inflammation or molecular mimicry, which leads the immune system to attack the body's own tissues and increases the risk of autoimmune diseases. Treatments for purpura play a crucial role in managing autoimmune diseases by suppressing the overactive immune response, enhancing platelet production, and reducing inflammation in blood vessels. This helps control symptoms like bruising, bleeding, and low platelet counts, which are commonly seen in autoimmune-related purpura such as immune thrombocytopenic purpura (ITP). For example, in March 2023, a report published by the Office for Health Improvement & Disparities, a UK government department, stated that in 2022, 17.6% of individuals aged 16 and above reported having a long-term musculoskeletal (MSK) condition, an increase from 17.0% in 2021. Thus, the rise in autoimmune disease prevalence is fueling the growth of the purpura treatment market.
The increasing demand for personalized medicine is also expected to boost the purpura treatment market. Personalized medicine involves tailoring medical treatments and practices to individual patients based on their genetic makeup, environmental factors, and lifestyle. This demand is being driven by advances in genomics and biotechnology, which allow for more precise and effective treatments tailored to individual genetic profiles, ultimately improving patient outcomes and minimizing side effects. In the context of purpura, personalized medicine uses genetic and immune system data to customize therapies, thereby improving treatment effectiveness and reducing adverse effects for patients based on their unique biological responses. For instance, according to the Personalized Medicine Coalition, a U.S.-based professional membership organization, in 2022, 12 newly approved personalized medicines accounted for approximately 34% of all new therapies approved that year, reflecting significant growth from previous years. Therefore, the growing interest in personalized medicine is contributing to the expansion of the purpura treatment market.
Leading companies in the purpura treatment market are prioritizing advancements in therapeutic options such as oral spleen tyrosine kinase (SYK) inhibitors to enhance treatment outcomes. These oral SYK inhibitors are medications that block the SYK enzyme, which plays a key role in the immune system's signaling processes. For example, in April 2023, Kissei Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, introduced TAVALISSE tablets (100 mg and 150 mg) in Japan as an oral treatment for adult patients with chronic idiopathic thrombocytopenic purpura (ITP). TAVALISSE (fostamatinib sodium hydrate) works by inhibiting the destruction of platelets by macrophages, thus improving bleeding symptoms in chronic ITP patients. It was approved in Japan following a Phase 3 clinical trial (R788-1301), where 36% of patients achieved a stable platelet response compared to 0% in the placebo group, demonstrating its effectiveness as a new treatment option.
Major players in the purpura treatment market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Limited, Intas Pharmaceuticals Ltd., Biogen Inc., Chugai Pharmaceutical Co Ltd., Sun Pharmaceutical Industries Limited, Octapharma AG, Grifols S.A., GC Pharma, Emergent BioSolutions Inc., Kissei Pharmaceutical Co Ltd., Ablynx N.V., Shire plc, Lee's Pharmaceutical Holdings Limited, Omeros Corporation, and KM Biologics Co Ltd.
North America was the largest region in the purpura treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in purpura treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the purpura treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The purpura treatment market consists of revenues earned by entities by providing services such as diagnostic evaluations, immunosuppressive therapy, intravenous immunoglobulin (IVIG) infusions, platelet transfusions, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The purpura treatment market also includes sales of products including corticosteroids, immunoglobulins (IVIG), biologics, immunosuppressants, and diagnostic kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Purpura Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on purpura treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for purpura treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The purpura treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Non-Thrombocytopenic Purpura; Thrombocytopenic Purpura; Allergic Purpura
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Purpura Treatment Market Characteristics
3. Purpura Treatment Market Trends And Strategies
4. Purpura Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Purpura Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Purpura Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Purpura Treatment Market Growth Rate Analysis
5.4. Global Purpura Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Purpura Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Purpura Treatment Total Addressable Market (TAM)
6. Purpura Treatment Market Segmentation
6.1. Global Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Thrombocytopenic Purpura
Thrombocytopenic Purpura
Allergic Purpura
6.2. Global Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Topical Treatments
Oral Medications
Intravitreal Injections
Laser Therapy
Photodynamic Therapy
6.3. Global Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute
Chronic
6.4. Global Purpura Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
6.5. Global Purpura Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other End-Users
6.6. Global Purpura Treatment Market, Sub-Segmentation Of Non-Thrombocytopenic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Idiopathic Purpura
Senile Purpura
Purpura Vascular Abnormalities
6.7. Global Purpura Treatment Market, Sub-Segmentation Of Thrombocytopenic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Thrombocytopenic Purpura (ITP)
Drug-induced Thrombocytopenic Purpura
Secondary Thrombocytopenic Purpura
6.8. Global Purpura Treatment Market, Sub-Segmentation Of Allergic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drug-Induced Allergic Purpura
Food-Induced Allergic Purpura
Infectious-related Allergic Purpura
7. Purpura Treatment Market Regional And Country Analysis
7.1. Global Purpura Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Purpura Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
